Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular

be the optimal treatment, compared with no preventive therapy, with an ICER of £2,020 per QALY gained (using the price of generic clopidogrel) and a difference in cost of £468 and 0.232 additional QALYs. 4.2.22 After consultation on the appraisal consultation document, the Assessment Group provided a reanalysis of the data for people who have had a myocardial infarction. This analysis used a price of clopidogrel of £5.13, reflecting the NHS tariff price for August 2010. The results showed that the lower price had no effect on the optimal treatment strategy: aspirin followed by clopidogrel remained the optimal treatment strategy. People with established peripheral arterial disease 4.2.23 The Assessment Group reported that for people with peripheral arterial disease the optimal treatment strategies were the same regardless of the price of clopidogrel. Clopidogrel followed by aspirin was the optimal strategy for this group, with an ICER of £2,815 per QALY gained. It was associated with an additional cost of £983 and an additional 0.349 QALYs compared with treatment with aspirin alone followed by treatment with clopidogrel. In people with intolerance to aspirin, clopidogrel alone was the optimal treatment strategy. Compared with no preventive therapy, clopidogrel gave an additional 0.773 QALYs at
